- CINCHOPHEN USP/EP/BP
-
- $1.10 / 1g
-
2021-06-10
- CAS:132-60-5
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons Min
|
| | CINCHOPHEN Basic information |
| | CINCHOPHEN Chemical Properties |
| Melting point | 214-215 °C (lit.) | | Boiling point | 392.37°C (rough estimate) | | density | 1.1426 (rough estimate) | | refractive index | 1.5300 (estimate) | | storage temp. | Keep in dark place,Sealed in dry,Room Temperature | | solubility | alcohol: soluble1g in 120ml(lit.) | | pka | 0.96±0.10(Predicted) | | form | Solid | | color | White | | Water Solubility | Insoluble in water | | Sensitive | Light Sensitive | | Merck | 14,2288 | | BRN | 192803 |
| | CINCHOPHEN Usage And Synthesis |
| Chemical Properties | BEIGE POWDER | | Uses | analgesic, antipyretic, antiinflammatory | | Uses | Cinchophen and its derivatives can show antipyretic, analgesic, anti-oxidative, and anti-inflammatory properties. | | Definition | ChEBI: 2-phenyl-4-quinolinecarboxylic acid is a member of quinolines. | | Brand name | Aglophenyl;Alcophenyl;Artexin;Atophan;Cefeno;Cinchophene;Cinconal;Cincosal;Fenofan;Iriphan;Mylofanol;Mylophanol;Phenoquin;Rhematan;Tervalon;Traubofan;Viophan. | | World Health Organization (WHO) | Cinchophen, an analgesic and antipyretic, was formerly available
in preparations for the treatment of gout. Its use was associated with adverse
effects including hepatitis, cirrhosis, skin lesions and angioneurotic oedema. WHO
has no information to suggest that preparations containing cinchophen remains
commercially available. | | Purification Methods | It crystallises from EtOH (ca 20mL/g), in several modifications with m 196o and 216o(subliming at 65o). [Beilstein 22 H 103, 22 II 518, 22 II 70, 22 III/IV 1358.] |
| | CINCHOPHEN Preparation Products And Raw materials |
|